ArticleInternational journal of general medicine2025
Comprehensive Analysis Reveals Biomarkers Related to Diabetic Peripheral Neuropathy and Its Molecular Mechanism.
Article in International journal of general medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Diabetic peripheral neuropathy (DPN) is a common complication of both type 1 and 2 diabetes. DPN lacks accurate early diagnostic indicators, prompting united identification of biomarkers through transcriptomics and Mendelian randomization (MR) to inform DPN prevention and treatment strategies. Patients and Methods: Differential expression analysis pinpointed DPN-related genes (DE-DPN-RGs) by screening differentially expressed genes (DEGs) across GSE95849 and GSE185011 datasets. MR approach validated DE-DPN-RGs causally linked to DPN as potential biomarkers, with sensitivity analysis and Steiger test reinforcing the findings. These biomarkers' expressions were verified via RT-qPCR, while their biological roles, pathways influencing DPN progression, and possible therapeutic targets were comprehensively investigated. Results: 124 DE-DPN-RGs were identified from 5340 DEGs1 and 896 DEGs2, among them, Conclusion: In conclusion,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.